NC
ARCT icon

NinePointTwo Capital’s Arcturus Therapeutics ARCT Stock Holding History

NinePointTwo Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,417
Closed -$184K – 192
2022
Q3 		$184K Hold
12,417
– – 0.07% 155
2022
Q2 		$195K Hold
12,417
– – 0.07% 173
2022
Q1 		$334K Buy
+12,417
New +$317K 0.09% 100

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

NinePointTwo Capital's ARCT Position: Q4 2022 in Review

NinePointTwo Capital sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 12,417 shares — an estimated $184K sold.

NinePointTwo Capital first reported a position in ARCT in Q1 2022 and held it in 3 quarters. The position peaked at $334K in Q1 2022. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

  • NinePointTwo Capital reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 12,417 Arcturus Therapeutics shares in Q4 2022, an estimated $184K.
  • NinePointTwo Capital first reported a position in Arcturus Therapeutics in Q1 2022 and held it in 3 quarters.
  • NinePointTwo Capital's Arcturus Therapeutics position peaked at $334K in Q1 2022.
  • 111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on NinePointTwo Capital's 13F filing for Q4 2022, filed 14 Feb 2023.